TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum titanium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial serum titanium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine titanium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical HSIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of discontinuation of drug
Endpoint domain: Adverse events/effects
Primary endpoint: Fear scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived threat likelihood scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Urinary 8-hydroxydeoxyguanosine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary 8-F2-isoprostanes Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hangover Symptom Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of target coping strategy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With Solicited Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functional connectivity coefficients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Appropriateness of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of cognitive dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in heart rate variability immediately after manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in heart rate variability 10 min after manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cardiac impedance immediately after manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cardiac impedance 10 minutes after manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure 10 minutes after manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in declarative memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total recall scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dual task response time (RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADHD Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in household food insecurity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of repeatability for usual and fast walk speeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of a Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bath Ankylosing Spondylitis Metrology Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation or relapse of psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive functioning based on MATRICS Consensus Cognitive Battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in patient response at level 3 of IPAQSS criterion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Worst Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute and chronic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Stroke and Systemic Embolism Events
Endpoint domain: Mortality/survival
Primary endpoint: First Occurrence of Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: First Occurrence of Any Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Return to Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Injured operated knee status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain experienced
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Correspondence between coverage maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time required to perform different functional tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of oxygen kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED90 of 0.5% Ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge pre- and post-test questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Practical skill score using rubric
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of students who were confident by self assessment using Likert scale questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Minimum dietary diversity during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily and final visual analog scale (VAS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Complete Response (nCR)/CR Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of Visits Where Moderate-to-high-strength Statins Are Appropriately Initiated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nightly CPAP Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients obtaining 5-12 oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Spontaneous Bowel Movements Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Self-perception of health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in release of GIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in release of GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in release of GLP-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in release of PYY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in release of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in combined levels of glucose and insulin, expressed in calculated indices for insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-year metastatic free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain reduction as assessed by the mean Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in daily life activities and quality of life using the Oswestry Low Back Pain Questionnaire (OLBPQ) and Short Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myotonometric evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain and Function Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of chronic GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of serrated lesions >=5mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean absolute difference in initial versus stable warfarin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Phosphocreatine kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive conjunctival culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-Emergent Adverse Events Leading to Study Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Largest diameter of abdominal lymphatic malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of the fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of intraoperative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in urinary albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in nephrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: volume of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: regional compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of early or unforeseen recourses to hospital for adverse event
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time until all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Time until heart-failure hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative predictive value of the 89Zr-trastuzumab PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days to Become Free of Narcotic Pain Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Mean Pre-hemodialysis Parathyroid Hormone (PTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sputum eosinophil % of total cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total time in minutes required to produce isolation of veins per WACA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total number of radiofrequency ablation lesions to produce isolation of veins per WACA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood levels of PH797804
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Myocardial Performance Index (Mod-MPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in PIPP Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent plasma clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central volume of distribution (V2/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady-state volume of distribution (Vss/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Area of Geographic Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Changes in the Levels of N-acetyl-aspartate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of undersensing of paroxysmal AF and AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in global levels of intraocular inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Minutes of Moderate to Vigorous Physical Activity (MVPA) Per Day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom From Aneurysm-Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Vaccine Response to Meningococcal Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency and type of KRAS mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of uterine scar defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Late cardiac toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ratio sFlt-1/PlGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: longest continuous period of cocaine abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incomplete resection rate of neoplastic polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient Reported Outcome Measurement Information System-29 (PROMIS-29)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Medical Research Council (MMRC) Dyspnea Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Charlson Comorbidity Index (CCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite incidence of Death, Re-transplantation or re-listed for transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Clinical evidence of CAV per ISHLT grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Penta 3 vaccine coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-hour urinary C-peptide response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduced bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for reintervention for bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Navigation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for Malignancy of System-Obtained Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Therapeutic cure after end of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Quality of echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Ventricular Energetic Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain at worst score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot function index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Retrieval Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Apparent Diffusion Coefficient (ADC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past year experience of physical violence by an intimate partner
Endpoint domain: Adverse events/effects
Primary endpoint: Past year experience of sexual violence by an intimate partner
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: myocardium metabolic and perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Longitudinal change in tau burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete closure of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the plasma semaglutide concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Crown failure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of blind participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of intraluminal tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anastomotic Leakage Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anastomotic Hemorrhage Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anastomotic Stenosis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Booster responses against Polio antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage change of skin tone index ITA° value of facial solar lentigines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of patients achieving ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Pain According to VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of administration associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs (blood pressure, respiratory rate, heart rate, body temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of recovery of the hip and knee joint articular amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with COVID-19 diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: SARS-Cov-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post procedural leaking at the needle insertion site
Endpoint domain: Adverse events/effects
Primary endpoint: plasma soluble urokinase plasminogen receptor (suPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conventional PSG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: Conjunctival Provocation Test (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance characteristics of the Predictive Biosciences Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Faces Pain Scale Revised (FPS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen Activity Normalized Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Clot Firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in the MCCB Working Memory Domain
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in the UPSA-VIM
Endpoint domain: Life impact
Endpoint subdomain: Functional status
Primary endpoint: Blood level of oral contraceptive pills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete Response Proportion (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Durable Complete Response Proportion (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HbA1c Values at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hypoglycemia Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clotting time changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Infarct size on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC CK-MB concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes